New hope for tough head and neck cancers?
NCT ID NCT05044897
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 34 times
Summary
This study tests a new drug, SI-B001, in 11 adults with advanced head and neck cancer that returned or spread after standard treatments. The goal is to see if the drug can shrink tumors or slow the disease. Participants receive the drug alone, and researchers monitor safety and how long any benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, 200000, China
-
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Conditions
Explore the condition pages connected to this study.